# Bigfoot Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bigfoot-biomedical

- Industry: Medical Devices & Equipment
- Headquarters: Milpitas, US
- Website: www.bigfootbiomedical.com
- Total disclosed funding: $127M
- Latest round: Series C (Jun 3, 2020)
- Investors on record: 9

## About

Based in the US, Bigfoot Biomedical, Inc. specializes in diabetes management solutions, notably through its innovative technology that integrates real-time data to enhance insulin dosing for individuals with diabetes.Founded in 2014 in Milpitas, California, Bigfoot Biomedical, Inc. focuses on developing diabetes management platforms. The company raised USD 9.20 mn in its Series C funding round led by Abbott Laboratories on September 4, 2023, contributing to a total of USD 9.20 mn raised to date. Founders Bryan Mazlish, Shane Lykins, and Susana Oliva have been instrumental in the company’s evolution as it aims to expand its offerings and market reach.Bigfoot Biomedical's core offering is the Bigfoot Unity Diabetes Management System, designed for individuals requiring multiple daily injections of insulin. This platform integrates real-time data from continuous glucose monitors, specifically utilizing the FreeStyle Libre 2 sensor, to provide personalized insulin dose recommendations. Aimed primarily at individuals diagnosed with Type 1 and Type 2 diabetes in the United States and select European markets, it enhances patient adherence through a connected device that delivers timely alerts and insights.The company generates revenue primarily through the sale of the Bigfoot Unity Diabetes Management System, which may involve direct sales, partnerships with healthcare providers, and collaborations with insurance companies. The business model includes subscription services for ongoing software updates and support, alongside agreements with wholesalers and retailers, emphasizing a comprehensive approach to diabetes management.With the recent acquisition by Abbott Laboratories in September 2023, Bigfoot Biomedical plans to utilize its funding to enhance product offerings and expand its market presence. The company is focused on the development of upcoming innovations in diabetes management, targeting broader access to its systems in new geographic regions, although specific release dates and targeted regions have yet to be disclosed.

## Funding rounds

- Series C, Jun 3, 2020, $9.2M — Abbott Laboratories, Cormorant Asset Management, Senvest Capital, Smile Group, Quadrant Capital Advisors, Janus Henderson Investors
- Series C, Dec 27, 2019, $46M — Abbott Laboratories, Janus Henderson Investors, Cormorant Asset Management, Senvest Capital, Quadrant Capital Advisors
- Series B, Nov 21, 2017, $37M — Cormorant Asset Management, Senvest Capital, Visionnaire Ventures, Janus Henderson Investors, Quadrant Capital Advisors, JDRF T1D Fund, Unitio, Inc
- Series A, Oct 19, 2016, $35M — Cormorant Asset Management, Senvest Capital, Visionnaire Ventures, Quadrant Capital Advisors

## Investors

- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A, Series B, Series C
- Senvest Capital (https://capitalatlas.ai/funds/senvest-capital) — Series A, Series B, Series C
- Visionnaire Ventures (https://capitalatlas.ai/funds/visionnaire-ventures) — Series A, Series B
- Quadrant Capital Advisors — Series A, Series B, Series C
- Janus Henderson Investors — Series B, Series C
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series B
- Unitio, Inc — Series B
- Abbott Laboratories — Series C
- Smile Group (https://capitalatlas.ai/funds/smile-group) — Series C